You are here

Eylea

FDA to review Regeneron’s Eylea for diabetic retinopathy

FDA to review Regeneron’s Eylea for diabetic retinopathy

Drug Delivery Business News

diabetic retinopathy

Flag link:

Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack

Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack

Endpoints

wet age-related macular degeneration

Flag link:

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Endpoints

wet age-related macular degeneration

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Yahoo/Benzinga

Pain Therapeutics

Vertex Pharmaceuticals

lumacaftor/ivacaftor

Flag link:

Regeneron plots DTC advertising and discount push to put Eylea back on track

Regeneron plots DTC advertising and discount push to put Eylea back on track

Fierce Pharma

DTC advertising

Flag link:

Allergan’s eye contender cannot knock Eylea off its perch

Allergan’s eye contender cannot knock Eylea off its perch

EP Vantage

wet age-related macular degeneration

Flag link:

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Market Realist

diabetic retinopathy

Flag link:

3 Reasons Regeneron Stock Could Start Climbing Again

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Flag link:

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Endpoints

wet age-related macular degeneration

Flag link:

Novartis sues Regeneron over manufacturing methods

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

drug manufacturing

Flag link:

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Xtalks

diabetic retinopathy

Flag link:

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

Endpoints

Flag link:

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Motley Fool

Flag link:

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Fierce Pharma

Flag link:

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Endpoints

bispecific antibodies

Flag link:

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Drug Delivery Business News

Momenta Pharmaceuticals

diabetic macular edema

wet age-related macular degeneration

Flag link:

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

Endpoints

Flag link:

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

Motley Fool

Clovis Oncology

Flag link:

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Endpoints

Flag link:

Regeneron posts mixed Q1 results, Eylea growth slows

Regeneron posts mixed Q1 results, Eylea growth slows

Drug Delivery Business News

Flag link:

Pages